الفهرس | Only 14 pages are availabe for public view |
Abstract The present study estimated that Xelox chrono may be an active first-line regimen in patients with mCRC. chronomodulated XELOX markedly reduce the overall toxicity, short term oxaliplatin infusion didn’t increase the severity of peripheral neuropathy. Regarding tolerance, xelox chrono showed better tolerance and fewer complications than standard 5FU-containing regimens. The toxicity most frequently encountered was vomiting (36%). The efficacy showed an ORR rate of 96% in chrono goup compared to 84% in xelox group and longer overall survival, after minimal follow up period of 6 months. In conclusion, the present chronomodulated XELOX regimen may reduce overall toxicity and improve efficacy; however, it cannot be excluded that a stricter adherence to the chronomodulated administration schedule could be beneficial. Furthermore, a 30-min infusion of oxaliplatin seems safe and does not increase the severity of peripheral neuropathy. |